Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELAVL1 | Q15717 | 7/20 | 0.55 |
| ▸ | HTR6 | P50406 | 6/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22130664 | 0.93 | ELAVL1 (0.50) | ELAVL1HTR6L3MBTL1RORC | |
| SCHEMBL22130662 | 0.92 | ELAVL1 (0.64) | ELAVL1HTR6KMT2ALMNASMN1; SMN2 | |
| SCHEMBL22130720 | 0.85 | ELAVL1 (0.59) | ELAVL1HTR6L3MBTL1 | |
| SCHEMBL22130731 | 0.84 | ELAVL1 (0.66) | ELAVL1HTR6KMT2ALMNASMN1; SMN2 | |
| SCHEMBL22130646 | 0.83 | ELAVL1 (0.56) | ELAVL1HTR6L3MBTL1KMT2ALMNA | |
| SCHEMBL22130723 | 0.82 | ELAVL1 (0.58) | ELAVL1HTR6L3MBTL1 | |
| SCHEMBL22130654 | 0.78 | ELAVL1 (0.59) | ELAVL1HTR6L3MBTL1KMT2ALMNA | |
| SCHEMBL22130732 | 0.78 | ELAVL1 (0.52) | ELAVL1HTR6L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL22130661 | 0.78 | ELAVL1 (0.65) | ELAVL1HTR6L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL21222570 | 0.77 | ELAVL1 (0.80) | ELAVL1HTR6L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689342-B2 | Aza-tanshinone derivatives, process for their preparation and their use in therapy | UNIVERSITA' DEGLI STUDI DI TRENTO (IT) | 2020-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689342-B2 | Aza-tanshinone derivatives, process for their preparation and their use in therapy | AZI2, TPMT, TYMS | ELAVL1 2765/4885HTR6 1922/4885L3MBTL1 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.